Dante Romanini is a notable inventor based in Sherman Oaks, California. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic compounds. With a total of four patents to his name, Romanini's work has the potential to impact the treatment of various diseases.

Latest Patents

One of his latest patents is titled "Bispecific antibodies with cleavable C-terminal charge-paired tags." This invention focuses on a CH3-containing molecule that includes a first polypeptide with a CH3 domain and a negatively charged domain, as well as a second polypeptide with a CH3 domain and a positively charged domain. The patent also outlines methods for conjugating synthetic molecules to a multi-specific antigen binding molecule. Another significant patent is for "Pegylated carfilzomib compounds," which provides a method for treating multiple myeloma using polymeric pegylated carfilzomib compounds and their pharmaceutically acceptable salts.

Career Highlights

Dante Romanini is currently associated with Amgen Inc., a leading biotechnology company known for its innovative therapies. His work at Amgen has allowed him to focus on developing cutting-edge treatments that address critical health challenges.

Collaborations

Throughout his career, Romanini has collaborated with esteemed colleagues, including Gary W. Luehr and Shabbir T.

This text is generated by artificial intelligence and may not be accurate.